SCHEMBL5758264

SCHEMBL5758264

Nc1ccc(C(=O)c2ccc(Cl)cc2)cc1C(=O)c1cccs1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.55
HPGD P15428 1/20 0.55
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
MAPT P10636 3/20 0.53
RAB9A P51151 4/20 0.52
LTC4S Q16873 1/20 0.48
ALDH1A1 P00352 2/20 0.48
ALOX15 P16050 2/20 0.48
PSMD14 O00487 1/20 0.48
MMP2 P08253 1/20 0.48
HSD17B10 Q99714 1/20 0.48
HPGDS O60760 1/20 0.47
CNR2 P34972 2/20 0.46
LMNA P02545 3/20 0.46
GAA P10253 1/20 0.46
NPC1 O15118 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5213288 0.87 RECQL (0.55) HTTHPGDMEN1KMT2AMAPT
SCHEMBL5591866 0.82 HPGDS (0.69) HTTHPGDMEN1KMT2AMAPT
SCHEMBL5758571 0.80 RAB9A (0.50) HTTMEN1KMT2AMAPTRAB9A
SCHEMBL11232876 0.78 HPGDS (0.53) HTTHPGDMEN1KMT2AMAPT
SCHEMBL8291933 0.77 HPGD (0.67) HTTHPGDMEN1KMT2AMAPT
SCHEMBL6351799 0.75 RECQL (0.64) HTTMEN1KMT2AMAPTRAB9A
SCHEMBL3984529 0.75 MAPT (0.57) HTTHPGDMEN1KMT2AMAPT
SCHEMBL1424601 0.74 ALOX15 (0.66) HTTHPGDMEN1KMT2AMAPT
SCHEMBL11755917 0.73 SMN1; SMN2 (0.68) HPGDMEN1KMT2AMAPTRAB9A
SCHEMBL6793430 0.73 HPGDS (0.83) HTTHPGDMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060135769-A1 Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives ANGIBAUD PATRICK R 2006-06-22 US disclosed
EP-1351954-B1 FARNESYL TRANSFERASE INHIBITING 4-HETEROCYCLYL-QUINOLINE AND QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2006-05-03 EP disclosed
US-20040067968-A1 Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline JANSSEN PHARMACEUTICA, N.V. (BE) 2004-04-08 US disclosed
EP-1351954-A1 FARNESYL TRANSFERASE INHIBITING 4-HETEROCYCLYL-QUINOLINE AND QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2003-10-15 EP disclosed
WO-2002051834-A1 FARNESYL TRANSFERASE INHIBITING 4-HETEROCYCLYL-QUINOLINE AND QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067968-A1 Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline FNTA, FNTB, ACAT2 HTT 4526/4885HPGD 1791/4885MEN1 1226/4885
US-20060135769-A1 Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives FNTA, FNTB, RABGGTB HTT 4268/4885HPGD 1425/4885MEN1 858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.